Traversa Sergio is listed as a director on 2 SEC Form D filings by 1 issuer in Sep 2023: EnZeta Immunotherapies, Inc. (Coral Gables, FL — biotechnology — 2023; $840K reported sold to 10 investors).
What this means One deal on file with the SEC, filed Sep 2023. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Paul Kelly (2 shared filings).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Traversa. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Traversa Sergio and found 1 difference: Form D filed 18 days after the first sale.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.